WO2001019400A3 - Pharmazeutische zusammensetzung in form eines nukleinsäure-lipid-komplexes, ihre herstellung und verwendung in der gentherapie - Google Patents
Pharmazeutische zusammensetzung in form eines nukleinsäure-lipid-komplexes, ihre herstellung und verwendung in der gentherapie Download PDFInfo
- Publication number
- WO2001019400A3 WO2001019400A3 PCT/EP2000/008996 EP0008996W WO0119400A3 WO 2001019400 A3 WO2001019400 A3 WO 2001019400A3 EP 0008996 W EP0008996 W EP 0008996W WO 0119400 A3 WO0119400 A3 WO 0119400A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- pharmaceutical composition
- gene therapy
- production
- acid lipid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU16388/01A AU1638801A (en) | 1999-09-15 | 2000-09-14 | Pharmaceutical composition in the form of a nucleic acid lipid complex, the production thereof and its use in gene therapy |
EP00967678A EP1216027A2 (de) | 1999-09-15 | 2000-09-14 | Pharmazeutische zusammensetzung in form eines nukleinsäure-lipid-komplexes, ihre herstellung und verwendung in der gentherapie |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19944262.2 | 1999-09-15 | ||
DE1999144262 DE19944262A1 (de) | 1999-09-15 | 1999-09-15 | Pharmazeutische Zusammensetzung in Form eines Nukleinsäure-Lipid-Komplexes, ihre Herstellung und Verwendung in der Gentherapie |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001019400A2 WO2001019400A2 (de) | 2001-03-22 |
WO2001019400A3 true WO2001019400A3 (de) | 2002-02-14 |
Family
ID=7922150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/008996 WO2001019400A2 (de) | 1999-09-15 | 2000-09-14 | Pharmazeutische zusammensetzung in form eines nukleinsäure-lipid-komplexes, ihre herstellung und verwendung in der gentherapie |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1216027A2 (de) |
AU (1) | AU1638801A (de) |
DE (1) | DE19944262A1 (de) |
WO (1) | WO2001019400A2 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1512393A1 (de) * | 2003-09-08 | 2005-03-09 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Verfahren zur Herstellung von homogenen Liposomen und Lipoplexen |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996018372A2 (en) * | 1994-12-09 | 1996-06-20 | Genzyme Corporation | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
WO1996020208A2 (de) * | 1994-12-28 | 1996-07-04 | Max-Delbrück-Centrum für Molekulare Medizin | Neues cholesterolderivat für den liposomalen gentransfer |
WO1996024333A1 (en) * | 1995-02-10 | 1996-08-15 | California Institute Of Technology | Lipid constructs for targeting to vascular smooth muscle tissue |
WO1996027393A1 (en) * | 1995-03-07 | 1996-09-12 | University Of Pittsburgh | A dry powder formulation for gene therapy |
WO1996034109A1 (en) * | 1995-04-25 | 1996-10-31 | Vical Incorporated | Single-vial formulations of dna/lipid complexes |
WO1996040067A1 (en) * | 1995-06-07 | 1996-12-19 | Aronex Pharmaceuticals, Inc. | Cationic lipid acid salt of 3 beta [n-(n',n'-dimethylaminoethane)-carbamoyl] cholesterol |
WO1996040964A2 (en) * | 1995-06-07 | 1996-12-19 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
WO1996040265A1 (en) * | 1995-06-07 | 1996-12-19 | The Regents Of The University Of California | Stabilization of polynucleotide complexes |
US5658565A (en) * | 1994-06-24 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Inducible nitric oxide synthase gene for treatment of disease |
WO1998044934A1 (en) * | 1997-04-07 | 1998-10-15 | Rutgers, The State University Of New Jersey | Cytokine and cisplatin-based gene therapy of carcinomas |
EP0891780A2 (de) * | 1997-07-11 | 1999-01-20 | Cardiogene Gentherapeutische Systeme AG | Transfektionssystem, seine Herstellung und Verwendung in der somatischen Gentherapie |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4411402A1 (de) * | 1994-03-31 | 1995-10-05 | Juergen Schrader | DNA-Expressionsvektoren zur Verwendung in der gentherapeutischen Behandlung von Gefäßerkrankungen |
US5811406A (en) * | 1995-06-07 | 1998-09-22 | Regents Of The University Of California | Dry powder formulations of polynucleotide complexes |
WO1998008489A1 (en) * | 1996-08-26 | 1998-03-05 | Transgene S.A. | Cationic lipid-nucleic acid complexes |
-
1999
- 1999-09-15 DE DE1999144262 patent/DE19944262A1/de not_active Withdrawn
-
2000
- 2000-09-14 AU AU16388/01A patent/AU1638801A/en not_active Abandoned
- 2000-09-14 EP EP00967678A patent/EP1216027A2/de not_active Withdrawn
- 2000-09-14 WO PCT/EP2000/008996 patent/WO2001019400A2/de not_active Application Discontinuation
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5658565A (en) * | 1994-06-24 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Inducible nitric oxide synthase gene for treatment of disease |
WO1996018372A2 (en) * | 1994-12-09 | 1996-06-20 | Genzyme Corporation | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
WO1996020208A2 (de) * | 1994-12-28 | 1996-07-04 | Max-Delbrück-Centrum für Molekulare Medizin | Neues cholesterolderivat für den liposomalen gentransfer |
WO1996024333A1 (en) * | 1995-02-10 | 1996-08-15 | California Institute Of Technology | Lipid constructs for targeting to vascular smooth muscle tissue |
WO1996027393A1 (en) * | 1995-03-07 | 1996-09-12 | University Of Pittsburgh | A dry powder formulation for gene therapy |
WO1996034109A1 (en) * | 1995-04-25 | 1996-10-31 | Vical Incorporated | Single-vial formulations of dna/lipid complexes |
WO1996040067A1 (en) * | 1995-06-07 | 1996-12-19 | Aronex Pharmaceuticals, Inc. | Cationic lipid acid salt of 3 beta [n-(n',n'-dimethylaminoethane)-carbamoyl] cholesterol |
WO1996040964A2 (en) * | 1995-06-07 | 1996-12-19 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
WO1996040265A1 (en) * | 1995-06-07 | 1996-12-19 | The Regents Of The University Of California | Stabilization of polynucleotide complexes |
WO1998044934A1 (en) * | 1997-04-07 | 1998-10-15 | Rutgers, The State University Of New Jersey | Cytokine and cisplatin-based gene therapy of carcinomas |
EP0891780A2 (de) * | 1997-07-11 | 1999-01-20 | Cardiogene Gentherapeutische Systeme AG | Transfektionssystem, seine Herstellung und Verwendung in der somatischen Gentherapie |
Non-Patent Citations (3)
Title |
---|
ANCHORDOQUY, THOMAS J. ET AL: "Maintenance of transfection rates and physical characterization of lipid/ DNA complexes after freeze-drying and rehydration", ARCH. BIOCHEM. BIOPHYS. (1997), 348(1), 199-206, XP000992258 * |
GAO X ET AL: "A NOVEL CATIONIC LIPOSOME REAGENT FOR EFFICIENT TRANSFECTION OF MAMMALIAN CELLS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 179, no. 1, 30 August 1991 (1991-08-30), pages 280 - 285, XP000572654, ISSN: 0006-291X * |
NABEL, ELIZABETH G. ET AL: "Methods for liposome-mediated gene transfer to the arterial wall", GENE THER. PROTOC. (1997), 127-133. EDITOR(S): ROBBINS, PAUL D. PUBLISHER: HUMANA, TOTOWA, N. J., XP000992423 * |
Also Published As
Publication number | Publication date |
---|---|
DE19944262A1 (de) | 2001-03-29 |
AU1638801A (en) | 2001-04-17 |
EP1216027A2 (de) | 2002-06-26 |
WO2001019400A2 (de) | 2001-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1311285E (pt) | Composicao farmaceutica liquida contendo um derivado de eritropoietina | |
IL197339A (en) | Recombinant chimeric uricase protein, protein-containing linker and preparations containing them | |
WO2001079444A3 (en) | Albumin fusion proteins | |
WO2001095899A8 (en) | Pharmaceutical compositions comprising cannabidiol derivatives | |
BR0109650A (pt) | 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca | |
EP0911039A3 (de) | Wirkstoff-Harzkomplexe stabilisiert mit Chelatbildner | |
GR3034204T3 (en) | Lipopolyamines as transfection agents and pharmaceutical uses thereof | |
EP1340765A3 (de) | Invertierte Chimäre und Hybrid-Oligonukleotide | |
CA2196780A1 (en) | A liposomal delivery system comprising cationic lipopolyamines and neutral lipids for delivery of biologically active agents | |
AU6985691A (en) | Pharmaceutical and cosmetic compositions | |
IL112664A0 (en) | 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them | |
AU5812400A (en) | Carrier-drug conjugate | |
BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
HU9403567D0 (en) | Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof | |
BR1100315A (pt) | Processo para melhorar a imunogenicidade de um imunogênio ou de um hapteno, gene de fusão, vetor de dna, medicamento e utilização de um complexo entre um imunogênio e uma mólecula | |
MXPA03009553A (es) | Uso de acido biliar o conjugados de acidos grasos de sales biliares. | |
WO2001034641A3 (en) | Antimicrobial activity of the first cationic cluster of human lactoferrin | |
WO2001019400A3 (de) | Pharmazeutische zusammensetzung in form eines nukleinsäure-lipid-komplexes, ihre herstellung und verwendung in der gentherapie | |
BR9714632A (pt) | Preparado de combinação farmacêutica, processo para a produção de preparados de combinações farmacêuticas, utilização de preparados de eritropoietina, e de ferro, e unidade de acondicionamento farmacêutica | |
ZA984845B (en) | New class of cationic transfecting agents for nucleic acids | |
EP1023906A4 (de) | Verstärker für antikörper gegen lymphoiden tumor | |
WO2000037613A3 (en) | Human akt-3 | |
BR0010034A (pt) | Utilização de um vetor, processo de preparação de um medicamento útil para a prevenção, a melhoria e/ou o tratamento da hipertensão arterial pulmonar, e, composição farmacêutica | |
BR0108757A (pt) | Peptìdeos memno processo para a preparação dos mesmos e uso dos mesmos | |
AU5698094A (en) | Antisense nucleic acid for the treatment of diseases in which expression of bfgf, pdgf-a or pdgf-b plays a pathogenic role |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA CN CZ HU ID IL IN JP KR NO PL RU SG SI SK TR US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA CN CZ HU ID IL IN JP KR NO PL RU SG SI SK TR US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000967678 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000967678 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10088248 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000967678 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |